Analysts Set Apyx Medical Corporation (NASDAQ:APYX) Price Target at $6.50

Apyx Medical Corporation (NASDAQ:APYX) has been given a consensus rating of “Moderate Buy” by the six research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $6.50.

A number of analysts have recently issued reports on APYX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research note on Friday, March 27th. Craig Hallum increased their price objective on shares of Apyx Medical from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Wall Street Zen cut shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. Finally, BTIG Research raised shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Wednesday, March 11th.

Apyx Medical Stock Down 3.9%

Shares of APYX stock opened at $3.99 on Monday. Apyx Medical has a 12 month low of $1.41 and a 12 month high of $4.50. The stock has a market cap of $167.06 million, a P/E ratio of -18.14 and a beta of 1.35. The company has a current ratio of 5.80, a quick ratio of 4.79 and a debt-to-equity ratio of 2.68. The company has a 50 day simple moving average of $3.80 and a two-hundred day simple moving average of $3.79.

Apyx Medical (NASDAQ:APYX) last announced its earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The business had revenue of $12.49 million during the quarter, compared to analysts’ expectations of $10.53 million.

Institutional Trading of Apyx Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Perkins Capital Management Inc. increased its stake in shares of Apyx Medical by 4.9% in the fourth quarter. Perkins Capital Management Inc. now owns 85,000 shares of the company’s stock worth $298,000 after purchasing an additional 4,000 shares in the last quarter. State Street Corp increased its stake in shares of Apyx Medical by 6.8% in the fourth quarter. State Street Corp now owns 116,706 shares of the company’s stock worth $408,000 after purchasing an additional 7,400 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Apyx Medical by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 358,829 shares of the company’s stock worth $1,257,000 after purchasing an additional 7,551 shares in the last quarter. Silverberg Bernstein Capital Management LLC grew its stake in Apyx Medical by 0.8% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock valued at $3,842,000 after acquiring an additional 8,067 shares in the last quarter. Finally, Nwam LLC purchased a new position in Apyx Medical during the first quarter valued at $47,000. 55.33% of the stock is owned by hedge funds and other institutional investors.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.